Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 17

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

438

HTML

3552

Tables (1-1)

204

Sum=4194

May 7, 2009 (publication date) through Nov 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. May 7, 2009; 15(17): 2067-2073
Published online May 7, 2009. doi: 10.3748/wjg.15.2067

Table 1 Side effects associated with anti-TNF therapy

Side effect	Example
Infections	Tuberculosis, histoplasmosis
Antibody formation	Antibodies to infliximab, antibodies to adalimumab
Infusion reactions	Anaphylaxis, delayed-type hypersensitivity
Autoimmunity	Antinuclear antibodies
Malignancies	Hepatosplenic T-cell lymphoma
Demyelization	Guillain-Barré syndrome
Abnormal liver function tests	Hepatitis, cholestatic disease
Cardiac abnormalities	Heart failure
Skin eruptions	Psoriasiform dermatitis

Citation: Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15(17): 2067-2073
URL: https://www.wjgnet.com/1007-9327/full/v15/i17/2067.htm
DOI: https://dx.doi.org/10.3748/wjg.15.2067